Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab

Abstract Although the phase III SUNLIGHT trial has demonstrated the survival benefit of the addition of bevacizumab (Bmab) to trifluridine/thymidine phosphorylase inhibitor (FTD/TPI), neutropenia, which frequently occurs during FDT/TPI + Bmab therapy, is a concern for clinicians. As TPI is excreted...

Full description

Saved in:
Bibliographic Details
Main Authors: Masatsune Shibutani, Hideki Tanda, Hiroaki Kasashima, Tatsunari Fukuoka, Shinichiro Kashiwagi, Kiyoshi Maeda
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Colorectal cancer
Trifluridine/thymidine phosphorylase inhibitor
Bevacizumab
Neutropenia
Renal function
Online Access:https://doi.org/10.1038/s41598-024-84133-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-84133-5

Similar Items